COVID-19 Impact on Global PD-1 Inhibitor Market Size, Status and Forecast 2020-2026
![](/report_cover/6975/covid-19-impact-on-global-pd-1-inhibitor-market-size-status-n-forecast-2020-2026_en.gif)
This report focuses on the global PD-1 Inhibitor status, future forecast, growth opportunity, key market and key players. The study objectives are to present the PD-1 Inhibitor development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study
The key players covered in this study
- Merck
- Novartis
- Onxeo
- Sumitomo Dainippon Pharma
- Taiwan Liposome Company
- Tiziana Life Sciences
- Genentech (Roche)
- AstraZeneca
- Pfizer
- Pembrolizumab
- Nivolumab
- Atezolizumab
- Durvalumab
- Avelumab
- Other
- Melanoma
- Non-small Cell Lung Cancer (NSCLC)
- Urothelial Carcinoma
- Classical Hodgkin Lymphoma
- Renal Cell Carcinoma
- Other
- North America
- Europe
- China
- Japan
- Southeast Asia
- India
- Central & South America
- To analyze global PD-1 Inhibitor status, future forecast, growth opportunity, key market and key players.
- To present the PD-1 Inhibitor development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
- To strategically profile the key players and comprehensively analyze their development plan and strategies.
- To define, describe and forecast the market by type, market and key regions.
- History Year: 2015-2019
- Base Year: 2019
- Estimated Year: 2020
- Forecast Year 2020 to 2026
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by PD-1 Inhibitor Revenue
1.4 Market Analysis by Type
1.4.1 Global PD-1 Inhibitor Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Pembrolizumab
1.4.3 Nivolumab
1.4.4 Atezolizumab
1.4.5 Durvalumab
1.4.6 Avelumab
1.4.7 Other
1.5 Market by Application
1.5.1 Global PD-1 Inhibitor Market Share by Application: 2020 VS 2026
1.5.2 Melanoma
1.5.3 Non-small Cell Lung Cancer (NSCLC)
1.5.4 Urothelial Carcinoma
1.5.5 Classical Hodgkin Lymphoma
1.5.6 Renal Cell Carcinoma
1.5.7 Other
1.6 Coronavirus Disease 2019 (Covid-19): PD-1 Inhibitor Industry Impact
1.6.1 How the Covid-19 is Affecting the PD-1 Inhibitor Industry
1.6.1.1 PD-1 Inhibitor Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and PD-1 Inhibitor Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for PD-1 Inhibitor Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 GLOBAL GROWTH TRENDS BY REGIONS
2.1 PD-1 Inhibitor Market Perspective (2015-2026)
2.2 PD-1 Inhibitor Growth Trends by Regions
2.2.1 PD-1 Inhibitor Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 PD-1 Inhibitor Historic Market Share by Regions (2015-2020)
2.2.3 PD-1 Inhibitor Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 PD-1 Inhibitor Market Growth Strategy
2.3.6 Primary Interviews with Key PD-1 Inhibitor Players (Opinion Leaders)
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top PD-1 Inhibitor Players by Market Size
3.1.1 Global Top PD-1 Inhibitor Players by Revenue (2015-2020)
3.1.2 Global PD-1 Inhibitor Revenue Market Share by Players (2015-2020)
3.1.3 Global PD-1 Inhibitor Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global PD-1 Inhibitor Market Concentration Ratio
3.2.1 Global PD-1 Inhibitor Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by PD-1 Inhibitor Revenue in 2019
3.3 PD-1 Inhibitor Key Players Head office and Area Served
3.4 Key Players PD-1 Inhibitor Product Solution and Service
3.5 Date of Enter into PD-1 Inhibitor Market
3.6 Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global PD-1 Inhibitor Historic Market Size by Type (2015-2020)
4.2 Global PD-1 Inhibitor Forecasted Market Size by Type (2021-2026)
5 PD-1 INHIBITOR BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global PD-1 Inhibitor Market Size by Application (2015-2020)
5.2 Global PD-1 Inhibitor Forecasted Market Size by Application (2021-2026)
6 NORTH AMERICA
6.1 North America PD-1 Inhibitor Market Size (2015-2020)
6.2 PD-1 Inhibitor Key Players in North America (2019-2020)
6.3 North America PD-1 Inhibitor Market Size by Type (2015-2020)
6.4 North America PD-1 Inhibitor Market Size by Application (2015-2020)
7 EUROPE
7.1 Europe PD-1 Inhibitor Market Size (2015-2020)
7.2 PD-1 Inhibitor Key Players in Europe (2019-2020)
7.3 Europe PD-1 Inhibitor Market Size by Type (2015-2020)
7.4 Europe PD-1 Inhibitor Market Size by Application (2015-2020)
8 CHINA
8.1 China PD-1 Inhibitor Market Size (2015-2020)
8.2 PD-1 Inhibitor Key Players in China (2019-2020)
8.3 China PD-1 Inhibitor Market Size by Type (2015-2020)
8.4 China PD-1 Inhibitor Market Size by Application (2015-2020)
9 JAPAN
9.1 Japan PD-1 Inhibitor Market Size (2015-2020)
9.2 PD-1 Inhibitor Key Players in Japan (2019-2020)
9.3 Japan PD-1 Inhibitor Market Size by Type (2015-2020)
9.4 Japan PD-1 Inhibitor Market Size by Application (2015-2020)
10 SOUTHEAST ASIA
10.1 Southeast Asia PD-1 Inhibitor Market Size (2015-2020)
10.2 PD-1 Inhibitor Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia PD-1 Inhibitor Market Size by Type (2015-2020)
10.4 Southeast Asia PD-1 Inhibitor Market Size by Application (2015-2020)
11 INDIA
11.1 India PD-1 Inhibitor Market Size (2015-2020)
11.2 PD-1 Inhibitor Key Players in India (2019-2020)
11.3 India PD-1 Inhibitor Market Size by Type (2015-2020)
11.4 India PD-1 Inhibitor Market Size by Application (2015-2020)
12 CENTRAL & SOUTH AMERICA
12.1 Central & South America PD-1 Inhibitor Market Size (2015-2020)
12.2 PD-1 Inhibitor Key Players in Central & South America (2019-2020)
12.3 Central & South America PD-1 Inhibitor Market Size by Type (2015-2020)
12.4 Central & South America PD-1 Inhibitor Market Size by Application (2015-2020)
13 KEY PLAYERS PROFILES
13.1 Merck
13.1.1 Merck Company Details
13.1.2 Merck Business Overview and Its Total Revenue
13.1.3 Merck PD-1 Inhibitor Introduction
13.1.4 Merck Revenue in PD-1 Inhibitor Business (2015-2020))
13.1.5 Merck Recent Development
13.2 Novartis
13.2.1 Novartis Company Details
13.2.2 Novartis Business Overview and Its Total Revenue
13.2.3 Novartis PD-1 Inhibitor Introduction
13.2.4 Novartis Revenue in PD-1 Inhibitor Business (2015-2020)
13.2.5 Novartis Recent Development
13.3 Onxeo
13.3.1 Onxeo Company Details
13.3.2 Onxeo Business Overview and Its Total Revenue
13.3.3 Onxeo PD-1 Inhibitor Introduction
13.3.4 Onxeo Revenue in PD-1 Inhibitor Business (2015-2020)
13.3.5 Onxeo Recent Development
13.4 Sumitomo Dainippon Pharma
13.4.1 Sumitomo Dainippon Pharma Company Details
13.4.2 Sumitomo Dainippon Pharma Business Overview and Its Total Revenue
13.4.3 Sumitomo Dainippon Pharma PD-1 Inhibitor Introduction
13.4.4 Sumitomo Dainippon Pharma Revenue in PD-1 Inhibitor Business (2015-2020)
13.4.5 Sumitomo Dainippon Pharma Recent Development
13.5 Taiwan Liposome Company
13.5.1 Taiwan Liposome Company Company Details
13.5.2 Taiwan Liposome Company Business Overview and Its Total Revenue
13.5.3 Taiwan Liposome Company PD-1 Inhibitor Introduction
13.5.4 Taiwan Liposome Company Revenue in PD-1 Inhibitor Business (2015-2020)
13.5.5 Taiwan Liposome Company Recent Development
13.6 Tiziana Life Sciences
13.6.1 Tiziana Life Sciences Company Details
13.6.2 Tiziana Life Sciences Business Overview and Its Total Revenue
13.6.3 Tiziana Life Sciences PD-1 Inhibitor Introduction
13.6.4 Tiziana Life Sciences Revenue in PD-1 Inhibitor Business (2015-2020)
13.6.5 Tiziana Life Sciences Recent Development
13.7 Genentech (Roche)
13.7.1 Genentech (Roche) Company Details
13.7.2 Genentech (Roche) Business Overview and Its Total Revenue
13.7.3 Genentech (Roche) PD-1 Inhibitor Introduction
13.7.4 Genentech (Roche) Revenue in PD-1 Inhibitor Business (2015-2020)
13.7.5 Genentech (Roche) Recent Development
13.8 AstraZeneca
13.8.1 AstraZeneca Company Details
13.8.2 AstraZeneca Business Overview and Its Total Revenue
13.8.3 AstraZeneca PD-1 Inhibitor Introduction
13.8.4 AstraZeneca Revenue in PD-1 Inhibitor Business (2015-2020)
13.8.5 AstraZeneca Recent Development
13.9 Pfizer
13.9.1 Pfizer Company Details
13.9.2 Pfizer Business Overview and Its Total Revenue
13.9.3 Pfizer PD-1 Inhibitor Introduction
13.9.4 Pfizer Revenue in PD-1 Inhibitor Business (2015-2020)
13.9.5 Pfizer Recent Development
14 ANALYST'S VIEWPOINTS/CONCLUSIONS
15 APPENDIX
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by PD-1 Inhibitor Revenue
1.4 Market Analysis by Type
1.4.1 Global PD-1 Inhibitor Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Pembrolizumab
1.4.3 Nivolumab
1.4.4 Atezolizumab
1.4.5 Durvalumab
1.4.6 Avelumab
1.4.7 Other
1.5 Market by Application
1.5.1 Global PD-1 Inhibitor Market Share by Application: 2020 VS 2026
1.5.2 Melanoma
1.5.3 Non-small Cell Lung Cancer (NSCLC)
1.5.4 Urothelial Carcinoma
1.5.5 Classical Hodgkin Lymphoma
1.5.6 Renal Cell Carcinoma
1.5.7 Other
1.6 Coronavirus Disease 2019 (Covid-19): PD-1 Inhibitor Industry Impact
1.6.1 How the Covid-19 is Affecting the PD-1 Inhibitor Industry
1.6.1.1 PD-1 Inhibitor Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and PD-1 Inhibitor Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for PD-1 Inhibitor Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 GLOBAL GROWTH TRENDS BY REGIONS
2.1 PD-1 Inhibitor Market Perspective (2015-2026)
2.2 PD-1 Inhibitor Growth Trends by Regions
2.2.1 PD-1 Inhibitor Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 PD-1 Inhibitor Historic Market Share by Regions (2015-2020)
2.2.3 PD-1 Inhibitor Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 PD-1 Inhibitor Market Growth Strategy
2.3.6 Primary Interviews with Key PD-1 Inhibitor Players (Opinion Leaders)
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top PD-1 Inhibitor Players by Market Size
3.1.1 Global Top PD-1 Inhibitor Players by Revenue (2015-2020)
3.1.2 Global PD-1 Inhibitor Revenue Market Share by Players (2015-2020)
3.1.3 Global PD-1 Inhibitor Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global PD-1 Inhibitor Market Concentration Ratio
3.2.1 Global PD-1 Inhibitor Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by PD-1 Inhibitor Revenue in 2019
3.3 PD-1 Inhibitor Key Players Head office and Area Served
3.4 Key Players PD-1 Inhibitor Product Solution and Service
3.5 Date of Enter into PD-1 Inhibitor Market
3.6 Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global PD-1 Inhibitor Historic Market Size by Type (2015-2020)
4.2 Global PD-1 Inhibitor Forecasted Market Size by Type (2021-2026)
5 PD-1 INHIBITOR BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global PD-1 Inhibitor Market Size by Application (2015-2020)
5.2 Global PD-1 Inhibitor Forecasted Market Size by Application (2021-2026)
6 NORTH AMERICA
6.1 North America PD-1 Inhibitor Market Size (2015-2020)
6.2 PD-1 Inhibitor Key Players in North America (2019-2020)
6.3 North America PD-1 Inhibitor Market Size by Type (2015-2020)
6.4 North America PD-1 Inhibitor Market Size by Application (2015-2020)
7 EUROPE
7.1 Europe PD-1 Inhibitor Market Size (2015-2020)
7.2 PD-1 Inhibitor Key Players in Europe (2019-2020)
7.3 Europe PD-1 Inhibitor Market Size by Type (2015-2020)
7.4 Europe PD-1 Inhibitor Market Size by Application (2015-2020)
8 CHINA
8.1 China PD-1 Inhibitor Market Size (2015-2020)
8.2 PD-1 Inhibitor Key Players in China (2019-2020)
8.3 China PD-1 Inhibitor Market Size by Type (2015-2020)
8.4 China PD-1 Inhibitor Market Size by Application (2015-2020)
9 JAPAN
9.1 Japan PD-1 Inhibitor Market Size (2015-2020)
9.2 PD-1 Inhibitor Key Players in Japan (2019-2020)
9.3 Japan PD-1 Inhibitor Market Size by Type (2015-2020)
9.4 Japan PD-1 Inhibitor Market Size by Application (2015-2020)
10 SOUTHEAST ASIA
10.1 Southeast Asia PD-1 Inhibitor Market Size (2015-2020)
10.2 PD-1 Inhibitor Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia PD-1 Inhibitor Market Size by Type (2015-2020)
10.4 Southeast Asia PD-1 Inhibitor Market Size by Application (2015-2020)
11 INDIA
11.1 India PD-1 Inhibitor Market Size (2015-2020)
11.2 PD-1 Inhibitor Key Players in India (2019-2020)
11.3 India PD-1 Inhibitor Market Size by Type (2015-2020)
11.4 India PD-1 Inhibitor Market Size by Application (2015-2020)
12 CENTRAL & SOUTH AMERICA
12.1 Central & South America PD-1 Inhibitor Market Size (2015-2020)
12.2 PD-1 Inhibitor Key Players in Central & South America (2019-2020)
12.3 Central & South America PD-1 Inhibitor Market Size by Type (2015-2020)
12.4 Central & South America PD-1 Inhibitor Market Size by Application (2015-2020)
13 KEY PLAYERS PROFILES
13.1 Merck
13.1.1 Merck Company Details
13.1.2 Merck Business Overview and Its Total Revenue
13.1.3 Merck PD-1 Inhibitor Introduction
13.1.4 Merck Revenue in PD-1 Inhibitor Business (2015-2020))
13.1.5 Merck Recent Development
13.2 Novartis
13.2.1 Novartis Company Details
13.2.2 Novartis Business Overview and Its Total Revenue
13.2.3 Novartis PD-1 Inhibitor Introduction
13.2.4 Novartis Revenue in PD-1 Inhibitor Business (2015-2020)
13.2.5 Novartis Recent Development
13.3 Onxeo
13.3.1 Onxeo Company Details
13.3.2 Onxeo Business Overview and Its Total Revenue
13.3.3 Onxeo PD-1 Inhibitor Introduction
13.3.4 Onxeo Revenue in PD-1 Inhibitor Business (2015-2020)
13.3.5 Onxeo Recent Development
13.4 Sumitomo Dainippon Pharma
13.4.1 Sumitomo Dainippon Pharma Company Details
13.4.2 Sumitomo Dainippon Pharma Business Overview and Its Total Revenue
13.4.3 Sumitomo Dainippon Pharma PD-1 Inhibitor Introduction
13.4.4 Sumitomo Dainippon Pharma Revenue in PD-1 Inhibitor Business (2015-2020)
13.4.5 Sumitomo Dainippon Pharma Recent Development
13.5 Taiwan Liposome Company
13.5.1 Taiwan Liposome Company Company Details
13.5.2 Taiwan Liposome Company Business Overview and Its Total Revenue
13.5.3 Taiwan Liposome Company PD-1 Inhibitor Introduction
13.5.4 Taiwan Liposome Company Revenue in PD-1 Inhibitor Business (2015-2020)
13.5.5 Taiwan Liposome Company Recent Development
13.6 Tiziana Life Sciences
13.6.1 Tiziana Life Sciences Company Details
13.6.2 Tiziana Life Sciences Business Overview and Its Total Revenue
13.6.3 Tiziana Life Sciences PD-1 Inhibitor Introduction
13.6.4 Tiziana Life Sciences Revenue in PD-1 Inhibitor Business (2015-2020)
13.6.5 Tiziana Life Sciences Recent Development
13.7 Genentech (Roche)
13.7.1 Genentech (Roche) Company Details
13.7.2 Genentech (Roche) Business Overview and Its Total Revenue
13.7.3 Genentech (Roche) PD-1 Inhibitor Introduction
13.7.4 Genentech (Roche) Revenue in PD-1 Inhibitor Business (2015-2020)
13.7.5 Genentech (Roche) Recent Development
13.8 AstraZeneca
13.8.1 AstraZeneca Company Details
13.8.2 AstraZeneca Business Overview and Its Total Revenue
13.8.3 AstraZeneca PD-1 Inhibitor Introduction
13.8.4 AstraZeneca Revenue in PD-1 Inhibitor Business (2015-2020)
13.8.5 AstraZeneca Recent Development
13.9 Pfizer
13.9.1 Pfizer Company Details
13.9.2 Pfizer Business Overview and Its Total Revenue
13.9.3 Pfizer PD-1 Inhibitor Introduction
13.9.4 Pfizer Revenue in PD-1 Inhibitor Business (2015-2020)
13.9.5 Pfizer Recent Development
14 ANALYST'S VIEWPOINTS/CONCLUSIONS
15 APPENDIX
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
LIST OF TABLES
Table 1. PD-1 Inhibitor Key Market Segments
Table 2. Key Players Covered: Ranking by PD-1 Inhibitor Revenue
Table 3. Ranking of Global Top PD-1 Inhibitor Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global PD-1 Inhibitor Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Pembrolizumab
Table 6. Key Players of Nivolumab
Table 7. Key Players of Atezolizumab
Table 8. Key Players of Durvalumab
Table 9. Key Players of Avelumab
Table 10. Key Players of Other
Table 11. COVID-19 Impact Global Market: (Four PD-1 Inhibitor Market Size Forecast Scenarios)
Table 12. Opportunities and Trends for PD-1 Inhibitor Players in the COVID-19 Landscape
Table 13. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 14. Key Regions/Countries Measures against Covid-19 Impact
Table 15. Proposal for PD-1 Inhibitor Players to Combat Covid-19 Impact
Table 16. Global PD-1 Inhibitor Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 17. Global PD-1 Inhibitor Market Size by Regions (US$ Million): 2020 VS 2026
Table 18. Global PD-1 Inhibitor Market Size by Regions (2015-2020) (US$ Million)
Table 19. Global PD-1 Inhibitor Market Share by Regions (2015-2020)
Table 20. Global PD-1 Inhibitor Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 21. Global PD-1 Inhibitor Market Share by Regions (2021-2026)
Table 22. Market Top Trends
Table 23. Key Drivers: Impact Analysis
Table 24. Key Challenges
Table 25. PD-1 Inhibitor Market Growth Strategy
Table 26. Main Points Interviewed from Key PD-1 Inhibitor Players
Table 27. Global PD-1 Inhibitor Revenue by Players (2015-2020) (Million US$)
Table 28. Global PD-1 Inhibitor Market Share by Players (2015-2020)
Table 29. Global Top PD-1 Inhibitor Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in PD-1 Inhibitor as of 2019)
Table 30. Global PD-1 Inhibitor by Players Market Concentration Ratio (CR5 and HHI)
Table 31. Key Players Headquarters and Area Served
Table 32. Key Players PD-1 Inhibitor Product Solution and Service
Table 33. Date of Enter into PD-1 Inhibitor Market
Table 34. Mergers & Acquisitions, Expansion Plans
Table 35. Global PD-1 Inhibitor Market Size by Type (2015-2020) (Million US$)
Table 36. Global PD-1 Inhibitor Market Size Share by Type (2015-2020)
Table 37. Global PD-1 Inhibitor Revenue Market Share by Type (2021-2026)
Table 38. Global PD-1 Inhibitor Market Size Share by Application (2015-2020)
Table 39. Global PD-1 Inhibitor Market Size by Application (2015-2020) (Million US$)
Table 40. Global PD-1 Inhibitor Market Size Share by Application (2021-2026)
Table 41. North America Key Players PD-1 Inhibitor Revenue (2019-2020) (Million US$)
Table 42. North America Key Players PD-1 Inhibitor Market Share (2019-2020)
Table 43. North America PD-1 Inhibitor Market Size by Type (2015-2020) (Million US$)
Table 44. North America PD-1 Inhibitor Market Share by Type (2015-2020)
Table 45. North America PD-1 Inhibitor Market Size by Application (2015-2020) (Million US$)
Table 46. North America PD-1 Inhibitor Market Share by Application (2015-2020)
Table 47. Europe Key Players PD-1 Inhibitor Revenue (2019-2020) (Million US$)
Table 48. Europe Key Players PD-1 Inhibitor Market Share (2019-2020)
Table 49. Europe PD-1 Inhibitor Market Size by Type (2015-2020) (Million US$)
Table 50. Europe PD-1 Inhibitor Market Share by Type (2015-2020)
Table 51. Europe PD-1 Inhibitor Market Size by Application (2015-2020) (Million US$)
Table 52. Europe PD-1 Inhibitor Market Share by Application (2015-2020)
Table 53. China Key Players PD-1 Inhibitor Revenue (2019-2020) (Million US$)
Table 54. China Key Players PD-1 Inhibitor Market Share (2019-2020)
Table 55. China PD-1 Inhibitor Market Size by Type (2015-2020) (Million US$)
Table 56. China PD-1 Inhibitor Market Share by Type (2015-2020)
Table 57. China PD-1 Inhibitor Market Size by Application (2015-2020) (Million US$)
Table 58. China PD-1 Inhibitor Market Share by Application (2015-2020)
Table 59. Japan Key Players PD-1 Inhibitor Revenue (2019-2020) (Million US$)
Table 60. Japan Key Players PD-1 Inhibitor Market Share (2019-2020)
Table 61. Japan PD-1 Inhibitor Market Size by Type (2015-2020) (Million US$)
Table 62. Japan PD-1 Inhibitor Market Share by Type (2015-2020)
Table 63. Japan PD-1 Inhibitor Market Size by Application (2015-2020) (Million US$)
Table 64. Japan PD-1 Inhibitor Market Share by Application (2015-2020)
Table 65. Southeast Asia Key Players PD-1 Inhibitor Revenue (2019-2020) (Million US$)
Table 66. Southeast Asia Key Players PD-1 Inhibitor Market Share (2019-2020)
Table 67. Southeast Asia PD-1 Inhibitor Market Size by Type (2015-2020) (Million US$)
Table 68. Southeast Asia PD-1 Inhibitor Market Share by Type (2015-2020)
Table 69. Southeast Asia PD-1 Inhibitor Market Size by Application (2015-2020) (Million US$)
Table 70. Southeast Asia PD-1 Inhibitor Market Share by Application (2015-2020)
Table 71. India Key Players PD-1 Inhibitor Revenue (2019-2020) (Million US$)
Table 72. India Key Players PD-1 Inhibitor Market Share (2019-2020)
Table 73. India PD-1 Inhibitor Market Size by Type (2015-2020) (Million US$)
Table 74. India PD-1 Inhibitor Market Share by Type (2015-2020)
Table 75. India PD-1 Inhibitor Market Size by Application (2015-2020) (Million US$)
Table 76. India PD-1 Inhibitor Market Share by Application (2015-2020)
Table 77. Central & South America Key Players PD-1 Inhibitor Revenue (2019-2020) (Million US$)
Table 78. Central & South America Key Players PD-1 Inhibitor Market Share (2019-2020)
Table 79. Central & South America PD-1 Inhibitor Market Size by Type (2015-2020) (Million US$)
Table 80. Central & South America PD-1 Inhibitor Market Share by Type (2015-2020)
Table 81. Central & South America PD-1 Inhibitor Market Size by Application (2015-2020) (Million US$)
Table 82. Central & South America PD-1 Inhibitor Market Share by Application (2015-2020)
Table 83. Merck Company Details
Table 84. Merck Business Overview
Table 85. Merck Product
Table 86. Merck Revenue in PD-1 Inhibitor Business (2015-2020) (Million US$)
Table 87. Merck Recent Development
Table 88. Novartis Company Details
Table 89. Novartis Business Overview
Table 90. Novartis Product
Table 91. Novartis Revenue in PD-1 Inhibitor Business (2015-2020) (Million US$)
Table 92. Novartis Recent Development
Table 93. Onxeo Company Details
Table 94. Onxeo Business Overview
Table 95. Onxeo Product
Table 96. Onxeo Revenue in PD-1 Inhibitor Business (2015-2020) (Million US$)
Table 97. Onxeo Recent Development
Table 98. Sumitomo Dainippon Pharma Company Details
Table 99. Sumitomo Dainippon Pharma Business Overview
Table 100. Sumitomo Dainippon Pharma Product
Table 101. Sumitomo Dainippon Pharma Revenue in PD-1 Inhibitor Business (2015-2020) (Million US$)
Table 102. Sumitomo Dainippon Pharma Recent Development
Table 103. Taiwan Liposome Company Company Details
Table 104. Taiwan Liposome Company Business Overview
Table 105. Taiwan Liposome Company Product
Table 106. Taiwan Liposome Company Revenue in PD-1 Inhibitor Business (2015-2020) (Million US$)
Table 107. Taiwan Liposome Company Recent Development
Table 108. Tiziana Life Sciences Company Details
Table 109. Tiziana Life Sciences Business Overview
Table 110. Tiziana Life Sciences Product
Table 111. Tiziana Life Sciences Revenue in PD-1 Inhibitor Business (2015-2020) (Million US$)
Table 112. Tiziana Life Sciences Recent Development
Table 113. Genentech (Roche) Company Details
Table 114. Genentech (Roche) Business Overview
Table 115. Genentech (Roche) Product
Table 116. Genentech (Roche) Revenue in PD-1 Inhibitor Business (2015-2020) (Million US$)
Table 117. Genentech (Roche) Recent Development
Table 118. AstraZeneca Business Overview
Table 119. AstraZeneca Product
Table 120. AstraZeneca Company Details
Table 121. AstraZeneca Revenue in PD-1 Inhibitor Business (2015-2020) (Million US$)
Table 122. AstraZeneca Recent Development
Table 123. Pfizer Company Details
Table 124. Pfizer Business Overview
Table 125. Pfizer Product
Table 126. Pfizer Revenue in PD-1 Inhibitor Business (2015-2020) (Million US$)
Table 127. Pfizer Recent Development
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
Table 1. PD-1 Inhibitor Key Market Segments
Table 2. Key Players Covered: Ranking by PD-1 Inhibitor Revenue
Table 3. Ranking of Global Top PD-1 Inhibitor Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global PD-1 Inhibitor Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Pembrolizumab
Table 6. Key Players of Nivolumab
Table 7. Key Players of Atezolizumab
Table 8. Key Players of Durvalumab
Table 9. Key Players of Avelumab
Table 10. Key Players of Other
Table 11. COVID-19 Impact Global Market: (Four PD-1 Inhibitor Market Size Forecast Scenarios)
Table 12. Opportunities and Trends for PD-1 Inhibitor Players in the COVID-19 Landscape
Table 13. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 14. Key Regions/Countries Measures against Covid-19 Impact
Table 15. Proposal for PD-1 Inhibitor Players to Combat Covid-19 Impact
Table 16. Global PD-1 Inhibitor Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 17. Global PD-1 Inhibitor Market Size by Regions (US$ Million): 2020 VS 2026
Table 18. Global PD-1 Inhibitor Market Size by Regions (2015-2020) (US$ Million)
Table 19. Global PD-1 Inhibitor Market Share by Regions (2015-2020)
Table 20. Global PD-1 Inhibitor Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 21. Global PD-1 Inhibitor Market Share by Regions (2021-2026)
Table 22. Market Top Trends
Table 23. Key Drivers: Impact Analysis
Table 24. Key Challenges
Table 25. PD-1 Inhibitor Market Growth Strategy
Table 26. Main Points Interviewed from Key PD-1 Inhibitor Players
Table 27. Global PD-1 Inhibitor Revenue by Players (2015-2020) (Million US$)
Table 28. Global PD-1 Inhibitor Market Share by Players (2015-2020)
Table 29. Global Top PD-1 Inhibitor Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in PD-1 Inhibitor as of 2019)
Table 30. Global PD-1 Inhibitor by Players Market Concentration Ratio (CR5 and HHI)
Table 31. Key Players Headquarters and Area Served
Table 32. Key Players PD-1 Inhibitor Product Solution and Service
Table 33. Date of Enter into PD-1 Inhibitor Market
Table 34. Mergers & Acquisitions, Expansion Plans
Table 35. Global PD-1 Inhibitor Market Size by Type (2015-2020) (Million US$)
Table 36. Global PD-1 Inhibitor Market Size Share by Type (2015-2020)
Table 37. Global PD-1 Inhibitor Revenue Market Share by Type (2021-2026)
Table 38. Global PD-1 Inhibitor Market Size Share by Application (2015-2020)
Table 39. Global PD-1 Inhibitor Market Size by Application (2015-2020) (Million US$)
Table 40. Global PD-1 Inhibitor Market Size Share by Application (2021-2026)
Table 41. North America Key Players PD-1 Inhibitor Revenue (2019-2020) (Million US$)
Table 42. North America Key Players PD-1 Inhibitor Market Share (2019-2020)
Table 43. North America PD-1 Inhibitor Market Size by Type (2015-2020) (Million US$)
Table 44. North America PD-1 Inhibitor Market Share by Type (2015-2020)
Table 45. North America PD-1 Inhibitor Market Size by Application (2015-2020) (Million US$)
Table 46. North America PD-1 Inhibitor Market Share by Application (2015-2020)
Table 47. Europe Key Players PD-1 Inhibitor Revenue (2019-2020) (Million US$)
Table 48. Europe Key Players PD-1 Inhibitor Market Share (2019-2020)
Table 49. Europe PD-1 Inhibitor Market Size by Type (2015-2020) (Million US$)
Table 50. Europe PD-1 Inhibitor Market Share by Type (2015-2020)
Table 51. Europe PD-1 Inhibitor Market Size by Application (2015-2020) (Million US$)
Table 52. Europe PD-1 Inhibitor Market Share by Application (2015-2020)
Table 53. China Key Players PD-1 Inhibitor Revenue (2019-2020) (Million US$)
Table 54. China Key Players PD-1 Inhibitor Market Share (2019-2020)
Table 55. China PD-1 Inhibitor Market Size by Type (2015-2020) (Million US$)
Table 56. China PD-1 Inhibitor Market Share by Type (2015-2020)
Table 57. China PD-1 Inhibitor Market Size by Application (2015-2020) (Million US$)
Table 58. China PD-1 Inhibitor Market Share by Application (2015-2020)
Table 59. Japan Key Players PD-1 Inhibitor Revenue (2019-2020) (Million US$)
Table 60. Japan Key Players PD-1 Inhibitor Market Share (2019-2020)
Table 61. Japan PD-1 Inhibitor Market Size by Type (2015-2020) (Million US$)
Table 62. Japan PD-1 Inhibitor Market Share by Type (2015-2020)
Table 63. Japan PD-1 Inhibitor Market Size by Application (2015-2020) (Million US$)
Table 64. Japan PD-1 Inhibitor Market Share by Application (2015-2020)
Table 65. Southeast Asia Key Players PD-1 Inhibitor Revenue (2019-2020) (Million US$)
Table 66. Southeast Asia Key Players PD-1 Inhibitor Market Share (2019-2020)
Table 67. Southeast Asia PD-1 Inhibitor Market Size by Type (2015-2020) (Million US$)
Table 68. Southeast Asia PD-1 Inhibitor Market Share by Type (2015-2020)
Table 69. Southeast Asia PD-1 Inhibitor Market Size by Application (2015-2020) (Million US$)
Table 70. Southeast Asia PD-1 Inhibitor Market Share by Application (2015-2020)
Table 71. India Key Players PD-1 Inhibitor Revenue (2019-2020) (Million US$)
Table 72. India Key Players PD-1 Inhibitor Market Share (2019-2020)
Table 73. India PD-1 Inhibitor Market Size by Type (2015-2020) (Million US$)
Table 74. India PD-1 Inhibitor Market Share by Type (2015-2020)
Table 75. India PD-1 Inhibitor Market Size by Application (2015-2020) (Million US$)
Table 76. India PD-1 Inhibitor Market Share by Application (2015-2020)
Table 77. Central & South America Key Players PD-1 Inhibitor Revenue (2019-2020) (Million US$)
Table 78. Central & South America Key Players PD-1 Inhibitor Market Share (2019-2020)
Table 79. Central & South America PD-1 Inhibitor Market Size by Type (2015-2020) (Million US$)
Table 80. Central & South America PD-1 Inhibitor Market Share by Type (2015-2020)
Table 81. Central & South America PD-1 Inhibitor Market Size by Application (2015-2020) (Million US$)
Table 82. Central & South America PD-1 Inhibitor Market Share by Application (2015-2020)
Table 83. Merck Company Details
Table 84. Merck Business Overview
Table 85. Merck Product
Table 86. Merck Revenue in PD-1 Inhibitor Business (2015-2020) (Million US$)
Table 87. Merck Recent Development
Table 88. Novartis Company Details
Table 89. Novartis Business Overview
Table 90. Novartis Product
Table 91. Novartis Revenue in PD-1 Inhibitor Business (2015-2020) (Million US$)
Table 92. Novartis Recent Development
Table 93. Onxeo Company Details
Table 94. Onxeo Business Overview
Table 95. Onxeo Product
Table 96. Onxeo Revenue in PD-1 Inhibitor Business (2015-2020) (Million US$)
Table 97. Onxeo Recent Development
Table 98. Sumitomo Dainippon Pharma Company Details
Table 99. Sumitomo Dainippon Pharma Business Overview
Table 100. Sumitomo Dainippon Pharma Product
Table 101. Sumitomo Dainippon Pharma Revenue in PD-1 Inhibitor Business (2015-2020) (Million US$)
Table 102. Sumitomo Dainippon Pharma Recent Development
Table 103. Taiwan Liposome Company Company Details
Table 104. Taiwan Liposome Company Business Overview
Table 105. Taiwan Liposome Company Product
Table 106. Taiwan Liposome Company Revenue in PD-1 Inhibitor Business (2015-2020) (Million US$)
Table 107. Taiwan Liposome Company Recent Development
Table 108. Tiziana Life Sciences Company Details
Table 109. Tiziana Life Sciences Business Overview
Table 110. Tiziana Life Sciences Product
Table 111. Tiziana Life Sciences Revenue in PD-1 Inhibitor Business (2015-2020) (Million US$)
Table 112. Tiziana Life Sciences Recent Development
Table 113. Genentech (Roche) Company Details
Table 114. Genentech (Roche) Business Overview
Table 115. Genentech (Roche) Product
Table 116. Genentech (Roche) Revenue in PD-1 Inhibitor Business (2015-2020) (Million US$)
Table 117. Genentech (Roche) Recent Development
Table 118. AstraZeneca Business Overview
Table 119. AstraZeneca Product
Table 120. AstraZeneca Company Details
Table 121. AstraZeneca Revenue in PD-1 Inhibitor Business (2015-2020) (Million US$)
Table 122. AstraZeneca Recent Development
Table 123. Pfizer Company Details
Table 124. Pfizer Business Overview
Table 125. Pfizer Product
Table 126. Pfizer Revenue in PD-1 Inhibitor Business (2015-2020) (Million US$)
Table 127. Pfizer Recent Development
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global PD-1 Inhibitor Market Share by Type: 2020 VS 2026
Figure 2. Pembrolizumab Features
Figure 3. Nivolumab Features
Figure 4. Atezolizumab Features
Figure 5. Durvalumab Features
Figure 6. Avelumab Features
Figure 7. Other Features
Figure 8. Global PD-1 Inhibitor Market Share by Application: 2020 VS 2026
Figure 9. Melanoma Case Studies
Figure 10. Non-small Cell Lung Cancer (NSCLC) Case Studies
Figure 11. Urothelial Carcinoma Case Studies
Figure 12. Classical Hodgkin Lymphoma Case Studies
Figure 13. Renal Cell Carcinoma Case Studies
Figure 14. Other Case Studies
Figure 15. PD-1 Inhibitor Report Years Considered
Figure 16. Global PD-1 Inhibitor Market Size YoY Growth 2015-2026 (US$ Million)
Figure 17. Global PD-1 Inhibitor Market Share by Regions: 2020 VS 2026
Figure 18. Global PD-1 Inhibitor Market Share by Regions (2021-2026)
Figure 19. Porter's Five Forces Analysis
Figure 20. Global PD-1 Inhibitor Market Share by Players in 2019
Figure 21. Global Top PD-1 Inhibitor Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in PD-1 Inhibitor as of 2019
Figure 22. The Top 10 and 5 Players Market Share by PD-1 Inhibitor Revenue in 2019
Figure 23. North America PD-1 Inhibitor Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Europe PD-1 Inhibitor Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. China PD-1 Inhibitor Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Japan PD-1 Inhibitor Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Southeast Asia PD-1 Inhibitor Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. India PD-1 Inhibitor Market Size YoY Growth (2015-2020) (Million US$)
Figure 29. Central & South America PD-1 Inhibitor Market Size YoY Growth (2015-2020) (Million US$)
Figure 30. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Merck Revenue Growth Rate in PD-1 Inhibitor Business (2015-2020)
Figure 32. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Novartis Revenue Growth Rate in PD-1 Inhibitor Business (2015-2020)
Figure 34. Onxeo Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. Onxeo Revenue Growth Rate in PD-1 Inhibitor Business (2015-2020)
Figure 36. Sumitomo Dainippon Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Sumitomo Dainippon Pharma Revenue Growth Rate in PD-1 Inhibitor Business (2015-2020)
Figure 38. Taiwan Liposome Company Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. Taiwan Liposome Company Revenue Growth Rate in PD-1 Inhibitor Business (2015-2020)
Figure 40. Tiziana Life Sciences Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. Tiziana Life Sciences Revenue Growth Rate in PD-1 Inhibitor Business (2015-2020)
Figure 42. Genentech (Roche) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 43. Genentech (Roche) Revenue Growth Rate in PD-1 Inhibitor Business (2015-2020)
Figure 44. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018
Figure 45. AstraZeneca Revenue Growth Rate in PD-1 Inhibitor Business (2015-2020)
Figure 46. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 47. Pfizer Revenue Growth Rate in PD-1 Inhibitor Business (2015-2020)
Figure 48. Bottom-up and Top-down Approaches for This Report
Figure 49. Data Triangulation
Figure 50. Key Executives Interviewed
Figure 1. Global PD-1 Inhibitor Market Share by Type: 2020 VS 2026
Figure 2. Pembrolizumab Features
Figure 3. Nivolumab Features
Figure 4. Atezolizumab Features
Figure 5. Durvalumab Features
Figure 6. Avelumab Features
Figure 7. Other Features
Figure 8. Global PD-1 Inhibitor Market Share by Application: 2020 VS 2026
Figure 9. Melanoma Case Studies
Figure 10. Non-small Cell Lung Cancer (NSCLC) Case Studies
Figure 11. Urothelial Carcinoma Case Studies
Figure 12. Classical Hodgkin Lymphoma Case Studies
Figure 13. Renal Cell Carcinoma Case Studies
Figure 14. Other Case Studies
Figure 15. PD-1 Inhibitor Report Years Considered
Figure 16. Global PD-1 Inhibitor Market Size YoY Growth 2015-2026 (US$ Million)
Figure 17. Global PD-1 Inhibitor Market Share by Regions: 2020 VS 2026
Figure 18. Global PD-1 Inhibitor Market Share by Regions (2021-2026)
Figure 19. Porter's Five Forces Analysis
Figure 20. Global PD-1 Inhibitor Market Share by Players in 2019
Figure 21. Global Top PD-1 Inhibitor Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in PD-1 Inhibitor as of 2019
Figure 22. The Top 10 and 5 Players Market Share by PD-1 Inhibitor Revenue in 2019
Figure 23. North America PD-1 Inhibitor Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Europe PD-1 Inhibitor Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. China PD-1 Inhibitor Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Japan PD-1 Inhibitor Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Southeast Asia PD-1 Inhibitor Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. India PD-1 Inhibitor Market Size YoY Growth (2015-2020) (Million US$)
Figure 29. Central & South America PD-1 Inhibitor Market Size YoY Growth (2015-2020) (Million US$)
Figure 30. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Merck Revenue Growth Rate in PD-1 Inhibitor Business (2015-2020)
Figure 32. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Novartis Revenue Growth Rate in PD-1 Inhibitor Business (2015-2020)
Figure 34. Onxeo Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. Onxeo Revenue Growth Rate in PD-1 Inhibitor Business (2015-2020)
Figure 36. Sumitomo Dainippon Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Sumitomo Dainippon Pharma Revenue Growth Rate in PD-1 Inhibitor Business (2015-2020)
Figure 38. Taiwan Liposome Company Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. Taiwan Liposome Company Revenue Growth Rate in PD-1 Inhibitor Business (2015-2020)
Figure 40. Tiziana Life Sciences Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. Tiziana Life Sciences Revenue Growth Rate in PD-1 Inhibitor Business (2015-2020)
Figure 42. Genentech (Roche) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 43. Genentech (Roche) Revenue Growth Rate in PD-1 Inhibitor Business (2015-2020)
Figure 44. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018
Figure 45. AstraZeneca Revenue Growth Rate in PD-1 Inhibitor Business (2015-2020)
Figure 46. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 47. Pfizer Revenue Growth Rate in PD-1 Inhibitor Business (2015-2020)
Figure 48. Bottom-up and Top-down Approaches for This Report
Figure 49. Data Triangulation
Figure 50. Key Executives Interviewed